Samsung BioLogics Co Ltd

207940: XKRX (KOR)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|vxh#wLOCK|K!S^LOCK|gQ&>tY

Samsung Bio Earnings: Guidance Raised for 2026 to Top End of Range As Utilization Increases

Samsung Bio third-quarter 2026 revenue grew 19% year on year to KRW 1.49 trillion, driven by full utilization of its plants and the ramp-up of its newest Plant 5. Operating margin declined by 710 basis points, and we believe this is due to ramp up and higher labor costs.

Sponsor Center